CLINICAL TRIALS PROFILE FOR EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

All Clinical Trials for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00013520 ↗	Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs). The current rule for starting treatment of HIV infection is to combine members from different classes of anti-HIV drugs, such as 2 nucleoside reverse transcriptase inhibitors (NRTIs) and either a PI or a nonnucleoside reverse transcriptase inhibitor (NNRTI). However, these combinations can be complicated and difficult to take, can cause a number of side effects, and may become ineffective. Combinations that are simpler, better tolerated, and more effective are needed. Because PIs can cause long-term side effects and because HIV can become resistant to many of them at the same time, anti-HIV combination treatments that do not use PIs are being tested.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	PENTA Foundation	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00050895 ↗	Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	With new strategies and drugs available, many different regimens exist for the treatment of HIV. The purpose of this study is to compare three different anti-HIV drug regimens as first-time treatments for HIV infection.

Clinical Trial Conditions for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

Condition Name

Condition Name for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate
Intervention	Trials
HIV Infections	11
HIV	3
HIV-1 Infection	3
Human Immunodeficiency Virus	2

Condition MeSH

Condition MeSH for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate
Intervention	Trials
HIV Infections	17
Acquired Immunodeficiency Syndrome	8
Immunologic Deficiency Syndromes	5
Infection	3

Clinical Trial Locations for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

Trials by Country

Trials by Country for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate
Location	Trials
United States	123
Germany	8
South Africa	6
Italy	5
United Kingdom	5

Trials by US State

Trials by US State for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate
Location	Trials
North Carolina	7
New York	7
Illinois	7
Florida	7
California	7

Clinical Trial Progress for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

Clinical Trial Phase

Clinical Trial Phase for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	14
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate
Clinical Trial Phase	Trials
Completed	19
Recruiting	3
Unknown status	3

Clinical Trial Sponsors for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

Sponsor Name

Sponsor Name for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	7
Gilead Sciences	6
Willem Daniel Francois Venter	3

Sponsor Type

Sponsor Type for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate
Sponsor	Trials
Other	33
Industry	16
NIH	8

Clinical Trials Update, Market Analysis, and Projection for Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate

Last updated: October 28, 2025

---

Introduction

The antiretroviral (ARV) combination comprising Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate (TDF) remains a cornerstone in the management of HIV/AIDS globally. As drug resistance, treatment guidelines, and patient demographics evolve, continuous assessment of clinical trials, market dynamics, and future projections is essential for pharmaceutical companies, healthcare providers, and policymakers. This article provides a comprehensive analysis of ongoing clinical trials, current market landscape, and future outlook for this ARV regimen.

---

Clinical Trials Horizon for Efavirenz, Lamivudine, and TDF

Ongoing Clinical Trials

The drug combination primarily aligns with branded formulations such as Atripla, which combine Efavirenz, Lamivudine, and TDF. While Atripla’s patent expired around 2018, generic versions have proliferated, prompting a renewed focus on newer formulations and combination strategies.

Current clinical trial activity mainly examines:

1. Emerging Resistance and Safety Profiles: Trials evaluate long-term safety, particularly neuropsychiatric effects associated with Efavirenz, and resistance patterns affecting regimen efficacy. For instance, NCT03543852 (evaluating neuropsychiatric adverse effects in diverse populations) underscores ongoing safety assessments.

2. Combination with Novel Agents: Trials aim to replace Efavirenz (due to side effects) with drugs like Dolutegravir or Bictegravir, resulting in integrase inhibitor-based regimens with similar efficacy but improved tolerability. For example, NCT03661015 assesses efficacy of integrase inhibitors versus Efavirenz in treatment-naïve patients.

3. Simplification and Pediatric Applications: Other trials target pediatric formulations and fixed-dose combinations to improve adherence. Trials like NCT03760883 explore dosing in children and adolescents.

4. Long-Term Effectiveness and Comorbidity Management: Several studies monitor co-infections (e.g., Hepatitis B and C) and comorbidities, analyzing combinations with TDF's activity against HBV as part of HIV treatment (e.g., NCT03734400).

Innovations and Future Directions

The clinical trial landscape is increasingly focused on:

• Integrase inhibitor-based regimens replacing Efavirenz-tied protocols due to side-effects.
• Long-acting injectable formulations (e.g., cabotegravir/rilpivirine) aiming for improved adherence.
• Pharmacogenetic studies to identify populations at higher risk of adverse effects, guiding personalized therapy.

Market Analysis

Current Market Landscape

The market for ARV drugs containing Efavirenz, Lamivudine, and TDF has undergone significant changes.

• Patent Expiry and Generics: Post-2018 patent expiration catalyzed a surge in generic formulations, sharply reducing prices and expanding access, especially in low-to-middle-income countries (LMICs). According to GlobalData, generic versions now constitute the majority of global sales.

• Geographic Distribution: Sub-Saharan Africa remains the dominant market, driven by international procurement programs (e.g., PEPFAR, Global Fund). The WHO's 2021 consolidated guidelines recommend TDF-based regimens universally, further boosting demand.

• Industry Dynamics: Major players include Mylan (now Viatris), Teva, and Cipla, which have leveraged cost-effective manufacturing. These generics often include combinations similar to the original branded drugs, expanding market reach.

• Side-effect Profile Impact: Efavirenz’s neuropsychiatric adverse effects have prompted shifts toward integrase inhibitor-based regimens (e.g., Dolutegravir-based), which are now increasingly replacing Efavirenz-containing drugs in high-income countries and some LMICs.

Market Challenges

• Side Effects and Resistance: Concerns over Efavirenz-related neurotoxicity and its potential to select for resistance diminish its attractiveness.
• Regulatory and Patent Disputes: Ongoing patent litigations and regulatory approvals influence market entry and competition.
• Availability of Alternatives: The rising adoption of newer drug classes diminishes the future market share for Efavirenz-based regimens.

Emerging Opportunities

• Fixed-dose combination (FDC) formulations (e.g., Atripla, Triumeq) streamline therapy and enhance adherence.
• Therapy simplification targeting specific populations (e.g., pregnant women, children).
• Efforts to expand access: Initiatives for low-cost generics encourage wider treatment coverage.

Market Projection (2023–2030)

Based on current trends, the market for Efavirenz, Lamivudine, and TDF-related drugs is poised to decline modestly in terms of brand-dominated sales, but overall volume will remain stable due to the continued need in LMICs.

• Short-term (2023–2025): The market will remain robust, primarily driven by generics serving global HIV treatment programs. The decline of Efavirenz-based branded products will be offset by the uptick in integrase inhibitor-based regimens.

• Mid-term (2025–2027): Adoption of newer agents and formulations will further reduce demand for Efavirenz combinations in high-income settings, while emerging economies maintain substantial growth.

• Long-term (2027–2030): Expected decline in Efavirenz and TDF-based regimens in favor of integrase inhibitors and long-acting injectables. However, significant market share persisted in resource-limited markets for older formulations until global treatment guidelines fully transition.

Forecasted CAGR for Efavirenz-Lamivudine-TDF formulations (2023–2030): Approximate decline of 3–5% annually, reflecting substitution trends but sustained global demand in LMICs.

---

Key Drivers & Barriers

Drivers	Barriers
Cost-effective generics	Neuropsychiatric side effects of Efavirenz
WHO treatment guidelines favoring TDF-based regimens	Rising resistance to NNRTIs
Global initiatives expanding access	Patent and regulatory constraints
Shift towards integrase inhibitors and long-acting injectables	Limited penetration of newer formulations in resource-limited settings

---

Conclusion

The clinical landscape for Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate is characterized by ongoing safety evaluations and evolving treatment paradigms favoring newer drug classes. Market-wise, while the demand for first-generation NNRTI-based regimens is projected to decline, their role remains vital in resource-constrained regions, bolstered by extensive generic manufacturing and existing supply chains. The global shift toward integrase inhibitors and long-acting formulations signals a transition, but legacy regimens will continue to underpin HIV treatment for years to come, particularly in low-income markets.

---

Key Takeaways

• Clinical trials are emphasizing safety, resistance, and regimen simplification, with a clear trend toward replacing Efavirenz with better-tolerated agents.
• The market has experienced a paradigm shift due to patent expirations, generic proliferation, and evolving treatment guidelines.
• Forecasts suggest a gradual decline in single-entity Efavirenz, Lamivudine, and TDF formulations, but they will remain crucial for accessible HIV therapy in developing regions.
• Innovations like integrase inhibitors and long-acting injectables are set to redefine HIV pharmacotherapy, impacting future formulations' demand.
• Stakeholders should monitor regulatory and patent developments, clinical trial outcomes, and macroeconomic factors influencing global drug access.

---

FAQs

1. What are the primary reasons for replacing Efavirenz in HIV regimens?
   Progress in understanding Efavirenz’s neuropsychiatric side effects, resistance issues, and availability of better-tolerated drugs like integrase inhibitors drive replacement efforts.

2. Are generic versions of Efavirenz, Lamivudine, and TDF reliable?
   Yes, multiple reputable manufacturers produce high-quality generics, significantly reducing costs and expanding access in LMICs.

3. What are the upcoming innovations in HIV therapy related to these drugs?
   Long-acting injectable formulations, fixed-dose combinations, and personalized therapy based on pharmacogenetic insights are emerging trends.

4. How will market demand shift globally in the next decade?
   Demand will decline in high-income countries due to newer therapies but remain stable or increase slightly in resource-limited settings until newer options achieve wider accessibility.

5. Are there ongoing clinical trials evaluating alternative combinations?
   Yes, ongoing studies assess integrase inhibitors, long-acting injectables, and novel agents that may replace Efavirenz-based regimens in future treatment algorithms.

---

References

1. [1] World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. 2021.
2. [2] GlobalData. HIV Market Report 2022.
3. [3] ClinicalTrials.gov. Search results for Efavirenz combinations.
4. [4] U.S. FDA. Drug Approvals and Regulatory History for Efavirenz and related formulations.
5. [5] UNAIDS. Global HIV & AIDS statistics — 2022.

---

Note: This analysis synthesizes publicly available data and expert insights up to the date of publication. Clinical trial statuses and market figures are subject to change as new data emerge.